Hwa Kyoung Shin1, Salvatore Salomone, Cenk Ayata. 1. Pusan National University, Medical Research Center for Ischemic Tissue Regeneration, 10 Ami-dong, 1-Ga, Seo-Gu, Busan 602-739, Korea.
Abstract
BACKGROUND: Rho and Rho-associated kinase (ROCK) play pivotal roles in pathogenesis of vascular diseases including stroke. ROCK is expressed in all cell types relevant to stroke, and regulates a range of physiological processes. OBJECTIVE: To provide an overview of ROCK as an experimental therapeutic target in cerebral ischemia, and the translational opportunities and obstacles in the prophylaxis and treatment of stroke. METHODS: Relevant literature was reviewed. RESULTS: ROCK activity is upregulated in chronic vascular risk factors such as diabetes, hyperlipidemia and hypertension, and more acutely by cerebral ischemia. ROCK activation is predicted to increase the risk of cerebral ischemia, and worsen the ischemic tissue outcome and functional recovery. Evidence suggests that ROCK inhibition is protective in models of cerebral ischemia. The benefit is mediated through multiple mechanisms. CONCLUSION: ROCK is a promising therapeutic target in all stages of stroke.
BACKGROUND: Rho and Rho-associated kinase (ROCK) play pivotal roles in pathogenesis of vascular diseases including stroke. ROCK is expressed in all cell types relevant to stroke, and regulates a range of physiological processes. OBJECTIVE: To provide an overview of ROCK as an experimental therapeutic target in cerebral ischemia, and the translational opportunities and obstacles in the prophylaxis and treatment of stroke. METHODS: Relevant literature was reviewed. RESULTS: ROCK activity is upregulated in chronic vascular risk factors such as diabetes, hyperlipidemia and hypertension, and more acutely by cerebral ischemia. ROCK activation is predicted to increase the risk of cerebral ischemia, and worsen the ischemic tissue outcome and functional recovery. Evidence suggests that ROCK inhibition is protective in models of cerebral ischemia. The benefit is mediated through multiple mechanisms. CONCLUSION: ROCK is a promising therapeutic target in all stages of stroke.
Authors: Salvatore Salomone; Guray Soydan; Peter Ching-Tze Ip; Kristen M Park Hopson; Christian Waeber Journal: Pharmacol Res Date: 2010-09-17 Impact factor: 7.658
Authors: Sanem A Aykan; Hongyu Xie; Yi Zheng; David Y Chung; Sreekanth Kura; James Han Lai; Taylan D Erdogan; Andreia Morais; Isra Tamim; Damla Yagmur; Hidehiro Ishikawa; Ken Arai; M Abbas Yaseen; David A Boas; Sava Sakadzic; Cenk Ayata Journal: Stroke Date: 2022-06-03 Impact factor: 10.170
Authors: Jeong Hyun Lee; Yi Zheng; Daniel von Bornstadt; Ying Wei; Aygul Balcioglu; Ali Daneshmand; Nilufer Yalcin; Esther Yu; Fanny Herisson; Yahya B Atalay; Maya Hwewon Kim; Yong-Joo Ahn; Mustafa Balkaya; Paul Sweetnam; Olivier Schueller; Masha V Poyurovsky; Hyung-Hwan Kim; Eng H Lo; Karen L Furie; Cenk Ayata Journal: Ann Clin Transl Neurol Date: 2014-01-01 Impact factor: 4.511